Guide

Ga-68 generator elution readiness for PET imaging sites

Ga-68 generators have moved diagnostic PET radiopharmaceuticals from the cyclotron-only model into the hospital and stand-alone imaging-center model. With a 68-minute half-life on Ga-68 and a 270-day half-life on the Ge-68 parent, a single generator supports 1–2 doses per elution and 2–3 elutions per day for up to 12 months. Ga-68-DOTATATE (NETSPOT, approved 2016) for neuroendocrine tumors and Ga-68-PSMA-11 (approved 2020) for prostate cancer are the volume drivers. This guide covers the operating model: generator qualification, elution discipline, breakthrough testing, automated labeling, and the controls that imaging-center inspectors look for.

Start free trial Free trial, no credit card, onboard in days, not months.

Generator landscape and qualification

Three commercial Ga-68 generators dominate: Eckert & Ziegler GalliaPharm (HCl elution, EU GMP grade), IRE ELiT Galli Eo (HCl, EU GMP), and Curium Galliad. Generators are FDA / EMA-registered as drug substances or active substances. Site qualification covers receipt-inspection, elution-yield verification on first elution, and breakthrough testing on every elution thereafter. Generator change-out at end-of-life (EOL) is a formal procedure with disposal documentation under 10 CFR 20 / EU radiation-protection rules.

Elution operations — the practical cycle

Pre-elution: hot-cell verification, dose calibrator constancy, automated synthesizer cassette change, precursor reconstitution (DOTATATE or PSMA-11 cold kit). Elution: 0.1 M HCl pumped through the generator into the synthesizer module; typical eluate volume 5–10 mL, activity 800–1850 MBq depending on generator age. Labeling: heated reaction at 95°C, solid-phase purification, sterile filtration. End-to-end time from elution to release ~30–45 minutes.

Breakthrough testing — the safety-critical control

Ge-68 breakthrough (parent isotope contamination of the daughter eluate) is the highest-risk QC parameter — a Ge-68 contaminated dose delivers the long-lived parent to the patient. Specification: Ge-68 breakthrough <0.001% of total activity (1 in 100,000). Test method: hold a small aliquot of eluate for ≥ 48 hours to let Ga-68 decay completely, then measure residual Ge-68 by gamma spectroscopy. The 48-hour wait means breakthrough is verified retrospectively, not pre-release — every elution is released on the validated assumption of breakthrough conformance based on the generator's qualification history.

Release model and conditional release

Release criteria: pH, appearance, radiochemical purity (HPLC and ITLC, ≥91% bound), radionuclidic identity (511 keV photopeak, half-life check), pyrogen / endotoxin (rapid LAL recommended given the 68-min half-life — a kinetic chromogenic assay returns in 15 minutes). Sterility is by membrane filtration at 0.22 µm; the post-release sterility test runs 14 days. This is the same conditional-release model as 21 CFR 212.70(f) — the 68-min Ga-68 half-life makes any other model physically impossible.

Inspection patterns

FDA, EMA, and state-board inspectors concentrate on: breakthrough trend records over the generator's life, automated-synthesizer cassette lot traceability, environmental monitoring of the hot cell and prep room, dose-calibrator linearity for the activity range used (especially at low activities late in generator life), and patient-specific dispense records. The most common 483 / deficiency in 2023–2025 is incomplete or generic environmental monitoring of the hot-cell critical zone.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

ALCOA+

The nine-letter mnemonic regulators use to grade your data integrity — and what every Part 11 audit really tests.

CAPA

Structured investigation + fix loop for recurring problems — required by every quality regime.

ICH Q10

The international model for a Pharmaceutical Quality System covering the entire product lifecycle from development to discontinuation.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Industries this hits hardest

Frequently asked

How many doses per generator per day are realistic?

A new generator (week 1–8) supports 2–3 elutions per day with 2 patient doses per elution. By month 6 yields drop and most sites elute once per day for 1 dose. End-of-life (typically 9–12 months) is driven by yield falling below clinical viability, not Ge-68 exhaustion — Ge-68 half-life of 270 days means there is always some Ga-68 available.

Can we re-use the eluate for two patients?

If both patients are scheduled within ~60 minutes of release and the dispensed activity is decay-corrected, yes — the labeling product is split into two patient-specific dispenses. Most sites schedule patients in pairs to optimize generator economics.

Is Ga-68 generator operation 21 CFR 212 or 211?

Neither, generally. NETSPOT and PSMA-11 manufacture under 21 CFR 212 is performed by the kit / generator manufacturer. The imaging site is doing prescription-pharmacy compounding under USP <825> or, in some configurations, distributing under an approved NDA. The boundary is set by state pharmacy law and whether interstate shipment occurs.

What happens if breakthrough fails the retrospective test?

Patient-notification protocol, deviation investigation, generator quarantine, regulatory notification. Because the test is retrospective, this is a known residual risk and the generator's design and qualification history are the primary controls.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →